Figure 2.

Plasma aminotransferase level (ALT) and hepatic angiotensin peptides levels in the BDL, CCl₄, and MCD models with ACE2 gene therapy. rAAV2/8-ACE2 treated animals displayed significant reduction of (a) plasma alanine aminotransferase (ALT). In addition, ACE2 therapy decreased (b) hepatic Ang II concentrations and (c) increased hepatic Ang-(1–7) concentrations. Each bar represents the mean ± SEM profile from n >10 mice per treatment group. *P < 0.0001, ^#P < 0.01 and ^P < 0.05 and were calculated by one-way analysis of variance with Tukey comparison test.